Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Scientists develop novel anticancer drug designed to travel through the bloodstream

Scientists develop novel anticancer drug designed to travel through the bloodstream

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

UTHealth professor receives ACS grant to improve care and QOL for people with liver cancer

UTHealth professor receives ACS grant to improve care and QOL for people with liver cancer

Scientists develop new animal model to study nonalcoholic steatohepatitis

Scientists develop new animal model to study nonalcoholic steatohepatitis

Cells close to death from toxin exposure can survive when toxins are removed

Cells close to death from toxin exposure can survive when toxins are removed

DKK1 boosts liver cancer diagnostic options

DKK1 boosts liver cancer diagnostic options

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

MRI scans determine whether chemotherapy is working long before tumors shrink

MRI scans determine whether chemotherapy is working long before tumors shrink

Cancer survivors benefit from healthy lifestyle

Cancer survivors benefit from healthy lifestyle

IU gastroenterologist develops first guidelines for diagnosis and management of NAFLD

IU gastroenterologist develops first guidelines for diagnosis and management of NAFLD

Rapid test to identify patients not responding to painkiller tramadol

Rapid test to identify patients not responding to painkiller tramadol

Simple blood test can quickly identify 'poor metabolisers'

Simple blood test can quickly identify 'poor metabolisers'

Piramal to present data on several molecular imaging compounds at SNM annual meeting

Piramal to present data on several molecular imaging compounds at SNM annual meeting

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex announces data from JX-594 clinical studies on cancer

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

75% increase in cancer incidence predicted by 2030

75% increase in cancer incidence predicted by 2030

Foreign-born populations in the U.S. are at increased risk for chronic HBV

Foreign-born populations in the U.S. are at increased risk for chronic HBV

Genetic analysis on Korean mummy reveals unique HBV genotype C2 sequence

Genetic analysis on Korean mummy reveals unique HBV genotype C2 sequence

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.